shr4640
Showing 1 - 11 of 11
Hyperuricemia Trial (SHR4640)
Not yet recruiting
- Hyperuricemia
- SHR4640
- (no location specified)
Jul 13, 2023
Hepatic Impairment Trial in Beijing (SHR4640)
Active, not recruiting
- Hepatic Impairment
- SHR4640
-
Beijing, Beijing, ChinaMeixia Wang
Aug 9, 2022
Gout Trial in Shanghai (SHR4640, Allopurinol)
Recruiting
- Gout
- SHR4640
- Allopurinol
-
Shanghai, Shanghai, ChinaRenJi Hospital, Shanghai JiaoTong University School Of Medicine
Jul 7, 2021
Healthy Subjects Trial (SHR4640)
Unknown status
- Healthy Subjects
- SHR4640
- (no location specified)
Nov 5, 2020
Primary Gout, Hyperuricemia Trial (SHR4640)
Unknown status
- Primary Gout
- Hyperuricemia
- SHR4640
- (no location specified)
Oct 9, 2020
Gout Trial in Suzhou (Colchicine, Febuxostat, SHR4640)
Completed
- Gout
- Colchicine
- +2 more
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Aug 6, 2019
Hyperuricemia Trial in Shanghai (Placebo, SHR4640, benzbromarone)
Completed
- Hyperuricemia
- Placebo
- +2 more
-
Shanghai, Shanghai, ChinaJiangsu Hengrui Medicine Co., Ltd.
Aug 5, 2019
Gout Trial in Sydney (SHR4640, Placebo)
Completed
- Gout
- SHR4640
- Placebo
-
Sydney, New South Wales, AustraliaAtridia Pty Limited
Jul 2, 2018
Gout, Hyperuricemia Trial in Sydney (SHR4640)
Completed
- Gout
- Hyperuricemia
- SHR4640
-
Sydney, New South Wales, AustraliaAtridia Pty Limited
Mar 20, 2018
Gout; Hyperuricemia Trial in Chongqing (SHR4640, )
Completed
- Gout; Hyperuricemia
- SHR4640
- placebo
-
Chongqing, Chongqing, ChinaThe South West Hospital
Mar 29, 2017
Gout; Hyperuricemia Trial in Chongqing (SHR4640, Placebo)
Completed
- Gout; Hyperuricemia
- SHR4640
- Placebo
-
Chongqing, Sichuan, ChinaSouthwest Hospital
Feb 26, 2017